Phathom Pharmaceuticals Earnings Call Signals VOQUEZNA Momentum
Phathom Pharmaceuticals (PHAT) reported Q3 revenue of $84.7M, up 71% YoY, with operating profit of $5.8M. VOQUEZNA prescriptions exceeded 2M, with 380K in Q3. Management highlighted strong payer coverage, cash position, and profitability outlook, but noted margin pressure and exclusivity litigation risks.
How this was made
The 30-second read
Why it matters
The call provides no new quantitative data beyond the prior release; investors are unlikely to adjust positions.
Market read
Recap of already‑published earnings; limited trading relevance.
What to watch
Potential litigation risk and margin pressure could become material if not resolved.
Background
Phathom Pharmaceuticals held its Q3 earnings call, reiterating strong revenue growth, profitability, and 2026 guidance.
Ticker impact
Recap of Q3 earnings call with revenue, profit, cash flow and reaffirmed 2026 guidance already disclosed earlier.
likely limited impact as information already priced
The article repeats numbers and guidance that were public 17 days ago; no new catalyst.
Market effects
None beyond reaffirming strength of the GERD drug market.
No regional effect noted.
Minimal.
Counterpoint
Even though the call is positive, the lack of new data suggests the stock may have already run up on the original release.
Key entities
- CompanyPhathom Pharmaceuticals
Developer of VOQUEZNA, a GERD treatment.



